TY - JOUR
T1 - Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients
AU - Bianco, Assunta
AU - Mari, Pier-Valerio
AU - Larici, Anna Rita
AU - Lucchini, Matteo
AU - Nociti, Viviana
AU - Losavio, Francesco Antonio
AU - De Fino, Chiara
AU - Cicchetti, Giuseppe
AU - Coraci, Daniele
AU - Richeldi, Luca
AU - Mirabella, Massimiliano
PY - 2020
Y1 - 2020
N2 - Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging.
AB - Background: Respiratory alemtuzumab-related adverse events are clinically heterogeneous and include respiratory infections, infusion-related dyspnea, hypoxia and secondary autoimmune disorders. Case report: Here we report three cases of drug-induced lung disease following treatment with alemtuzumab in multiple sclerosis patients. First case was diagnosed as a non-specified intestitial pneumonitis associated with organizing pneumonia with subacute onset, second case was an acute respiratory distress syndrome with onset during second cycle, third case was a diffuse acute alveolar hemorrhage during first cycle infusion. All patients developed acute respiratory failure, reversible after steroid therapy. Conclusions: Clinicians should be aware to early recognize acute and subacute respiratory adverse events for a promptly management. In these patients re-treatment is challenging.
KW - Acute respiratory distress syndrome
KW - Diffuse alveolar haemorrhage
KW - Interstitial pneumonitis
KW - Personalized medicine
KW - Pulmonary toxicity
KW - Acute respiratory distress syndrome
KW - Diffuse alveolar haemorrhage
KW - Interstitial pneumonitis
KW - Personalized medicine
KW - Pulmonary toxicity
UR - http://hdl.handle.net/10807/147357
UR - http://www.elsevier.com/wps/find/journaldescription.cws_home/725776/description#description
U2 - 10.1016/j.msard.2019.101450
DO - 10.1016/j.msard.2019.101450
M3 - Editorial
SN - 2211-0348
VL - 37
SP - 1
EP - 3
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
ER -